Apyx Medical Inc（APYX）資訊與事件APYXApyx Medical Inc

Company Expects Gross Margins of 63% to 65%

The company said, "The Company expects gross margins in the range of 63% to 65%. The Company now expects operating expenses in the range of $41.0 million to $42.5 million for the year ended December 31, 2026 down from the previous guidance of less than $45.0 million."

AYON Reports Q3 Revenue of $14.03M, 17% Growth

Reports Q3 revenue $14.03M, consensus $13.29M. "We are pleased to report 17% growth in our Surgical Aesthetics business for the quarter, reflecting continued adoption of AYON and the progress we are making in executing our commercial strategy," said Charlie Goodwin, President and Chief Executive Officer. "Over the past year, we have continued to demonstrate the value AYON offers by providing a full suite of complementary body contouring capabilities in one integrated platform. We are building on that foundation with the broader commercial launch of power liposuction, which has received very positive early feedback from surgeons since it received FDA clearance earlier this year. We estimate that approximately 70% of plastic surgeons use power liposuction, making this an important addition that broadens AYON's appeal."

Apyx Medical Releases Renuvion Study Results, Significant Skin Quality Improvement

Apyx Medical announced results from a prospective clinical study evaluating the effects of Renuvion helium plasma radiofrequency technology on biological markers of skin quality. The study was published in Plastic and Reconstructive Surgery-Global Open. Key Findings from the Study at Day 180 as compared to control tissue: Renuvion-treated tissue demonstrated a 30% increase in elastin fiber density and a 55% increase in elastin staining intensity, supporting improvements in a key component of skin elasticity and resilience. Treated tissue demonstrated a 34% reduction in inflammation compared with untreated control tissue, supporting a healthier tissue environment following treatment. Human tissue analysis demonstrated a 27% increase in the incidence of elastin expression. 100% of participants demonstrated improvement in both physician- and patient-assessed aesthetic improvement scores. 100% of participants reported improvement, were satisfied with their treatment outcomes and indicated they would recommend the procedure to others. 100% of participants reported noticeable improvements in skin elasticity, radiance and youthfulness, providing patient-reported support for the biological changes observed in treated tissue.